Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 1/20 | 0.37 |
| ▸ | PYGM | P11217 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100300 | 0.84 | ABL1 (0.43) | HTR4 | |
| SCHEMBL7114457 | 0.83 | HPGDS (0.36) | HTR4GRM5 | |
| SCHEMBL7114437 | 0.82 | LOX (0.40) | HTR4GRM5 | |
| SCHEMBL6100511 | 0.82 | SLC6A2 (0.42) | GRM5 | |
| SCHEMBL7121804 | 0.80 | KDR (0.40) | KDRRIPK1 | |
| SCHEMBL6101485 | 0.80 | GRM5 (0.40) | GRM5KDRPDE3BPDE3APYGL | |
| SCHEMBL6098618 | 0.80 | GRM5 (0.40) | GRM5KDRPYGLPYGMRIPK1 | |
| SCHEMBL6101770 | 0.78 | GRM5 (0.59) | GRM5KDR | |
| SCHEMBL7116456 | 0.78 | EGLN1 (0.39) | GRM5 | |
| SCHEMBL6098192 | 0.78 | HTR4 (0.43) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | HTR4 3671/4885GRM5 1965/4885KDR 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.